GESSEL advises Pure Biologics S.A., a company listed on the Warsaw Stock Exchange

GESSEL supported Pure Biologics S.A. and its shareholders in preparation of a prospect-less public share offering via the accelerated book building process and execution of a private share offering. The shares publicly offered comprised the newly issued G series as well as existing shares, which were made available to qualified investors and to selected retail investors, and for the private offering – newly issued H series shares. The aggregate value of the two share offerings was in the range of PLN 30 million.

The transaction was conducted on the basis of an investment and offering agreement executed by the company with IPOPEMA SECURITIES S.A. and a share placement agreement. In an interesting variant of what would be the typical deal structure, existing shares of the company already floated on the Warsaw Stock Exchange were loaned to the entity selling shares within the accelerated book building transaction; performance of the loan agreement will include return of the newly issued H series shares to the lending shareholders.

GESSEL assisted the company and its shareholders with all legal aspects of the transaction, in particular drawing up the company’s corporate documents, negotiation of the various agreements, and compliance with disclosure duties.

Pure Biologics, established in 2010, formulates and develops biological medicines and extracorporeal and in vitro therapies in the realms of immunooncology, autoimmunology, and rare neurological disorders. Its experiments with antibodies and aptamers are conducted using the company’s own technological platforms.